TDT has big impact on patients, families and society – POLITICO

References

¹Guaranello R and others Orphanet J Rare Dis. 2010; 5:11.

²Taher, Ali T et al. NEJM. 2021;384(8):727-743.

³N. Lee et al. Poster BSH23-OR05 was presented at his 2023 British Society of Hematology Conference on 23 April 2023.

^FourJobanputra M, et al. Br J Hematol. 2020; 191(5):897-905.

^FiveBrousse V et al. value in health. 2019;22:S851

⁶Sankaran VG, Orkin SH. Cold Spring Herbal Perspective Medicine.2013;3:a011643.

⁷The EU policy recommendations for thalassemia and sickle cell disease, TIF, are available at: https://thalassemia.org.cy/positions-policies/position-papers/# The access date is April 25, 2023.

⁸Musallam KM, et al. blood. 2012;119(2):364-367.

⁹Shelton E and others hepatitis journal 2016;2(1):11.

^TenDr. Cappellini et al. Management Guidelines for Transfusion-Dependent Thalassemia (TDT). Thalassemia International League, 4th Edition; 2021.

¹¹Lee et al. blood (2022) 140 (supplement 1): 10869–10870.

¹²Paramore C et al. Patient. 2021;14(2):197-208.

¹³Udeze, C. et al. 2023 ISPOR Abstract of EE58 published in May 2023.

¹⁴Kunzweiler C et al. 2023 ISPOR Abstract of EE62 published in May 2023.

¹⁵Udeze, C. et al. 2023 Abstract EE287 presented at ISPOR, May 2023

¹⁶Udeze, C., et al. Abstract 2793 presented at the 2022 European Society of Hematology Annual Meeting

¹⁷Socié G, Ritz J. Current issues in chronic graft-versus-host disease. blood. 2014 Jul 17;124(3):374-84.

¹⁸Udeze, C., et al. blood (2022) 140 (Supplement 1): 10741–10742.

¹⁹EMAs. An overview of the product properties of Ruspatercept. Available at: https://www.ema.europa.eu/en/documents/product-information/reblozyl-epar-product-information_en.pdf. Last access May 2023.

²⁰NICE 2022. Ruspatercept for treatment of anemia due to beta thalassemia (end of evaluation). Available at: https://www.nice.org.uk/guidance/ta843/resources/luspatercept-for-treating-anaemia-caused-by-betathalassaemia-terminated-appraisal-pdf-82613490074053. Last accessed: May 2023.

^{twenty one}HAS 2021. REBLOZYL 25 (luspatercept) – ß-thalassémie. Available at: https://www.has-sante.fr/jcms/p_3281010/fr/reblozyl-25-ss-thalassemie-luspatercept. Last accessed: May 2023.

^{twenty two}FDA. Zynteglo Prescribing Highlights. Available at: https://www.fda.gov/media/160991/download. Last accessed: May 2023.

^{twenty three}EMAs. Jin Tegro. Available at: https://www.ema.europa.eu/en/medicines/human/EPAR/zynteglo. Last accessed: May 2023.

^{twenty four}bluebird bio. Bluebird Bio Community Update. Available at: https://www.bluebirdbio.com/-/media/bluebirdbio/Corporate-COM/Files/bbbcom-community-update-letter.pdf. Last accessed: May 2023.